TENX SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 5, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Jul 31, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 12, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 10, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 12, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 13, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Tenax Therapeutics Reports Q3 2026 Financial Results and Provides Update on LEVEL-2 Clinical Trial Protocol Enrichment

Nov 5, 2026

8-K

Tenax Therapeutics Corporate Presentation Outlines Phase 3 LEVEL-2 Trial Plans and Data for Oral Levosimendan (TNX-103)

Oct 8, 2026

8-K

Tenax Therapeutics Reports Phase 3 LEVEL Clinical Trial Results for Levosimendan (TNX-103) in PH-HFpEF

Sep 9, 2026

8-K

Tenax Therapeutics Announces Topline Results from Phase 3 LEVEL Clinical Trial of TNX-103 in Patients with PH-HFpEF

Aug 10, 2026

8-K

Tenax Therapeutics Reports Q2 2026 Financial Results and Provides Clinical Trial Updates

Jul 31, 2026

8-K

Tenax Therapeutics to Present Phase 3 LEVEL Clinical Trial Data at ESC Congress 2026

Jul 2, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B3

UPDATED | SHARE RESALE REGISTRATION | Shares amount: 4,131,072 | Warrants amount: 3,760,7261

Apr 23, 2025

424B3

UPDATED | SHARE RESALE REGISTRATION | Shares amount: 49,600,000 | Warrants amount: 48,666,637 | Warrants exercise price: $4.50

Sep 12, 2024

424B3

UPDATED

Feb 26, 2024

424B3

UPDATED

Feb 26, 2024

424B3

UPDATED

Feb 21, 2024

424B3

UPDATED

Feb 21, 2024

Registrations

TYPE

HEADLINE

FILED AT

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

May 12, 2026

S-3

March 2026 SHELF

Mar 24, 2026

S-3

SHARE RESALE REGISTRATION | Shares amount: 4,151,072 | Warrants amount: 3,760,726 .01

Apr 15, 2025

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Nov 26, 2024

S-8

Registration

Aug 30, 2024

S-3

SHARE RESALE REGISTRATION | Shares amount: 16,666,666 | Warrants amount: 16,666,666 | Warrants exercise price: $4.50 EFFECTIVE

Aug 30, 2024

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 22, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 22, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 25, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 25, 2025

PRE 14A

Form PRE 14A - Other preliminary proxy statements

Apr 9, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Sep 27, 2024

Ownerships

TYPE

HEADLINE

FILED AT

SCHEDULE 13G/A

BlackRock, Inc. (Filed by)

Oct 27, 2026

Schneeberger Daniel (Reporting)

Oct 21, 2026

SCHEDULE 13G/A

MILLENNIUM MANAGEMENT LLC (Filed by)

Oct 15, 2026

SCHEDULE 13G/A

SPHERA FUNDS MANAGEMENT LTD. (Filed by)

Oct 13, 2026

SCHEDULE 13G/A

Dellora Investments LP (Filed by)

Oct 9, 2026

Doogan Declan (Reporting)

Sep 17, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Apr 2, 2026

CORRESP

Form CORRESP - Correspondence

Mar 31, 2026

LETTER

Form UPLOAD - SEC-generated letter

Mar 27, 2026

EFFECT

Form EFFECT - Notice of Effectiveness

Apr 24, 2025

CORRESP

Form CORRESP - Correspondence

Apr 21, 2025

LETTER

Form UPLOAD - SEC-generated letter

Apr 18, 2025

Tenax Therapeutics, Inc. TENX · SEC Filings